News

RELIEF THERAPEUTICS Holding SA announces that it has executed a binding Share Exchange Agreement (the “Agreement”) with Sonnet BioTherapeutics, Inc. ("Sonnet"). Sonnet is a privately…
Read More...

Neoleukin Therapeutics, Inc. announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. will be renamed…
Read More...

Amgen announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two patents that describe and claim Enbrel (etanercept) and…
Read More...

Cancer Research UK, the world’s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have announced a partnership to develop…
Read More...

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on…
Read More...

Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for a subcutaneous (SC)…
Read More...

Immunotherapy drug pembrolizumab (also known as Keytruda) used with chemotherapy drugs carboplatin and paclitaxel will now be an option for adults with squamous non-small-cell lung…
Read More...

Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced that it has signed a…
Read More...

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing…
Read More...

Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we…
Read More...

Vesselon (www.vesselon.com), an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent®. Vesselon will use Imagent to create novel therapeutic…
Read More...

Aquinox Pharmaceuticals, Inc. and Neoleukin Therapeutics, Inc. announced that the two companies entered into a definitive merger agreement under which Aquinox agreed to the acquisition…
Read More...

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven…
Read More...

A pivotal Phase 3 trial evaluating Dupixent (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first…
Read More...

Stoke Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new…
Read More...

GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire,…
Read More...

Bayer and LANXESS sell their stakes in the chemical park operator Currenta to funds managed by Macquarie Infrastructure and Real Assets (MIRA), the world's largest infrastructure…
Read More...

Roche announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq (atezolizumab)…
Read More...

Eli Lilly and Company announced that Emgality (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of…
Read More...